Jim Simons Satsuma Pharmaceuticals, Inc. Transaction History

Renaissance Technologies LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$0.7 - $1.07 $62,719 - $95,872	-89,600 Reduced 35.26%	164,500 $115,000
Q4 2022 Feb 13, 2023	BUY	$0.61 - $5.06 $148,901 - $1.24 Million	244,100 Added 2441.0%	254,100 $229,000
Q3 2022 Nov 14, 2022	BUY	$4.19 - $7.95 $41,900 - $79,500	10,000 New	10,000 $60,000
Q4 2021 Feb 11, 2022	SELL	$4.15 - $6.24 $172,905 - $259,983	-41,664 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$4.54 - $7.17 $71,800 - $113,393	-15,815 Reduced 27.51%	41,664 $194,000
Q2 2021 Aug 13, 2021	SELL	$4.8 - $7.25 $189,700 - $286,527	-39,521 Reduced 40.74%	57,479 $405,000
Q1 2021 May 13, 2021	BUY	$4.57 - $7.18 $359,087 - $564,168	78,575 Added 426.46%	97,000 $573,000
Q4 2020 Feb 10, 2021	BUY	$3.56 - $5.09 $65,593 - $93,783	18,425 New	18,425 $85,000

Ticker STSA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,587,500
Description
Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can ...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.